Results of the Surgical Treatment of Patients From Hepatobiliopancreatic Surgical Unit at the Complejo Hospitalario de Navarra

What this Trial Is About

Researchers are evaluating the outcomes of patients who have undergone surgery by the Hepatobiliopancreatic (HPB) Surgical Unit. The study aims to assess post-surgical morbidity and mortality based on international classifications, as well as survival and disease-free survival rates for patients treated surgically for tumoral causes. This observational study includes both retrospective and prospective data collection over a long-term period. The surgical treatments involve various techniques tailored to each patient’s specific condition, performed by the HPB Surgical Unit. The study includes patients operated on in the last 10 years and those undergoing surgery from January 2019 onward who consent to participate. There are no experimental drugs; instead, the focus is on observing outcomes following these surgical procedures. Participants’ health status is monitored for 90 days after surgery to assess morbidity and mortality, while survival and disease-free survival are tracked for up to 5 years. Researchers also evaluate the standardization of pre- and post-surgical care, the effectiveness of multimodal treatments, oncological quality standards, and minimally invasive surgical techniques. The study spans several years, allowing detailed follow-up and analysis of long-term surgical results.

Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit